This article is more than 5 years old. Information may no longer be current.
VIDEO: Innovation in CAR T-cell design may help improve safety, efficacy
NEW ORLEANS — Marco L. Davila, MD, PhD, medical oncologist at Moffitt Cancer Center, reacts to an abstract presented at the American Association for Cancer Research Annual Meeting that described a new innovation in chimeric antigen receptor T-cell therapy.
The researchers determined activation and inactivation of CAR T cells through a small molecule adaptor may allow for better control of the engineered cells, potentially helping to overcome some of the limitations previously observed with CAR T-cell therapy.
“This is an important innovation within CAR design,” Davila told HemOnc Today. “It’s certainly not the only innovation that has been proffered in the past year to meet safety and efficacy goals, but it has some promise.”